Zydus gets USFDA nod to market ranitidine Hcl injection

The group now has 76 approvals, has so far filed 172 ANDAs since the commencement of the filing process in FY04

Ahmedabad-based Zydus Cadila on Monday informed that the company has received the final approval from the US Foods and Drug Administration (USFDA) to market ranitidine Hcl injections in the US market.

“Used in the treatment of peptic ulcers, gastritis and gastroesophageal reflux disease (GERD), ranitidine Hcl falls in the anti-secretory segment. The company has received USFDA approval to market ranitidine Hcl injections 25 mg /ml,” the company informed in a statement issued today.

“The estimated sales in 2012 as per IMS for ranitidine Hcl injection had been around $5.4 million (approx. Rs 29.14 crore).

The group now has 76 approvals and has so far filed 172 ANDAs since the commencement of the filing process in FY 2003-04, the company stated.

Cadila Healthcare shares closed at Rs 774.95 on Bombay Stock Exchange (BSE) with marginal loss of 0.08 per cent from previous close.